Currently Viewing:
ACC 2017
Dr Rob Nolan Discusses Behavioral Foundations of eCounseling Programs
June 10, 2017
Dr Rob Nolan Explains Behavioral Principles Behind eCounseling Hypertension Program
May 15, 2017
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
May 10, 2017
Dr William Borden Discusses MACRA Requirements From a Cardiologist's Perspective
May 08, 2017
Dr Janet Wright on Cardiologists' Role in Public Health and Prevention Efforts
April 15, 2017
Dr Rob Nolan on the Future Directions of eCounseling Research
April 14, 2017
Dr Seth J. Baum Discusses Payers' Reluctance to Approve Coverage of PCSK9 Inhibitors
April 07, 2017
Dr Janet Wright Discusses How Million Hearts Will Leverage Partnerships for Success
April 06, 2017
Dr Robert P. Giugliano Discusses the Significance of the FOURIER and EBBINGHAUS Trials
April 06, 2017
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
March 20, 2017
Dr Jim McDermott Discusses Objectives and Outcomes of CVD-REAL Trial
March 20, 2017
Charting the Path to Health Equity: Steps for Providers
March 20, 2017
Dr Janet Wright Outlines Goals and Roadblocks of Million Hearts Initiative
March 20, 2017
Dr William Borden: Advice for Cardiologists on Adjusting to MACRA
March 19, 2017
Dr Rob Nolan Discusses Findings From REACH Hypertension eCounseling Trial
March 19, 2017
Can SGLT2 Inhibitors Prevent Heart Failure in a Broad Population?
March 19, 2017
Data Show It's Hard to Fill PCSK9 Prescriptions, Confirming Cardiologists' Complaints
March 19, 2017
Currently Reading
Dr Robert P. Giugliano on the Results of the EBBINGHAUS Evolocumab Cognitive Study
March 18, 2017
Bringing MACRA to Cardiologists, Ready or Not
March 17, 2017

Dr Robert P. Giugliano on the Results of the EBBINGHAUS Evolocumab Cognitive Study

Past study results had raised concerns about the effect of lipid-lowering drugs like evolocumab on cognitive function, but the EBBINGHAUS trial presented at the American College of Cardiology 66th Scientific Session may finally help put those fears to rest, explained lead study author Robert P. Giugliano, MD, MSc, associate professor of medicine at Harvard Medical School.


Past study results had raised concerns about the effect of lipid-lowering drugs like evolocumab on cognitive function, but the EBBINGHAUS trial presented at the American College of Cardiology 66th Scientific Session may finally help put those fears to rest, explained lead study author Robert P. Giugliano, MD, MSc, associate professor of medicine at Harvard Medical School.

Transcript (slightly modified)

Can you describe the EBBINGHAUS study and its results?

EBBINGHAUS was a trial of nearly 2000 patients, looking at various assessments of cognition, so memory and working memory and other kind of, orientation, planning, organization, things like that. We were interested in finding out whether this new drug, evolocumab, affects these cognitive parameters or not. There had been older data that suggested either statins or having a very low LDL was associated with impaired cognition. So EBBINGHAUS was a formal study designed to look at cognition of evolocumab, a PCSK9 inhibitor, compared with placebo.

There were, as I mentioned, just under 2000 patients randomized. They underwent a battery of cognitive tests and we also had them fill out questionnaires at the end of the study, which lasted almost 2 years, and tell us what they felt about their memory, organization, planning skills, et cetera, compared to the beginning of the trial. And then the third part of it is we looked at physician-reported cognitive adverse events to see if physicians picked up that there were problems with memory, orientation, planning, et cetera.

There were no differences between evolocumab, the drug, and placebo in any of these measures. Furthermore, we also did an exploratory analysis where we looked at patients according to their achieved LDL. In this trial we got the LDLs down very, very low; on average 30 mg/dL, but we looked at a group who were below 25, 25 to 40, 40 and above, and there were no differences according to the achieved LDL in their cognitive function or between the 2 treatments.

What are the implications of these results for evolocumab’s approval for a broader patient population?

Some clinicians and even the FDA had raised concerns about possible effects on cognition of lipid-lowering drugs, particularly statins, and some earlier data with the PCSK9 inhibitors suggested there may be an association of use of these drugs with impaired cognition. I think what the clinician should take home from this study is that in a dedicated, prospective trial looking at cognition in a variety of different ways, there’s no effect of the drug compared to placebo, even when you looked at the patients who achieved very low LDLs. So I think this information’s reassuring for the clinicians, that they can use these drugs safely without patients having impaired cognition or problems with memory, things like that.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!